SIRONAX

Aging is not a disease, but it is often accompanied by a complex array of chronic degenerative diseases. Sironax is committed to promoting healthier aging by targeting the underlying mechanisms of degeneration across various organs and tissues, including neuronal/axonal degeneration, muscle degeneration, epithelial cell death, neuroinflammation, and oxidative stress... Since our founding, we have been hard at work developing our pathway-driven portfolio strategy which has enabled us to establish a pipeline of novel therapies that address a wide range of age-related degenerative diseases and underlying mechanisms, including regulated cell death, NAD+ pathway modulations, neuroprotective pathways, neuroinflammation, among others. To date, our pipeline contains more than five innovative programs spanning small and large molecules, all of which are global first-in-class or front-runners. Our lead RIPK1 program is comprised of several chemically differentiated small molecule inhibitors,..

Also known as: Sironax Ltd.

Primary location: Beijing China